Evidence map›Paper›PMID 40290844›Full record

ReviewEClinicalMedicine2025

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.

Geeta Sandhu, Josephine Adattini, Evangeline Armstrong Gordon, Niamh O'Neill, Corrinne Bagnis, Alan V Boddy, Pinkie Chambers, Alex Flynn, Brett Hamilton, Karim Ibrahim and 30 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Geeta SandhuFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Josephine AdattinieviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Evangeline Armstrong GordoneviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Niamh O'NeilleviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Corrinne BagnisNephrology Department, APHP Sorbonne University, and GRIFON, Paris, France.
Alan V BoddySchool of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Pinkie ChambersUniversity College London School of Pharmacy and University College London Hospital-University College London Centre for Medicines Optimisation Research and Education, London, United Kingdom.
Alex FlynnCentre for Drug Repurposing, University of Newcastle, Newcastle, NSW, Australia.
Brett HamiltonAlbury Wodonga Cancer Care, West Albury, NSW, Australia.
Karim IbrahimFaculty of Medicine and Health, The University of New South Wales, Sydney, NSW, Australia.
David W JohnsonAustralasian Kidney Trials Network, The University of Queensland, Brisbane, QLD, Australia.
Christos KarapetisFlinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia.
Aisling KellyeviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Kimberley-Ann KerrSA Health, Adelaide, SA, Australia.
Ganessan KichenadasseFlinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia.
David S KlimanDepartment of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia.
Craig KurkardUniversity of Newcastle, Newcastle, NSW, Australia.
Winston LiauwCancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
Catherine LucasCentre for Drug Repurposing, University of Newcastle, Newcastle, NSW, Australia.
Andrew J MallettDepartment of Renal Medicine, Townsville University Hospital, Townsville, QLD, Australia.
Jolanta MalyszkoDepartment of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Georgia McCaughanSchool of Clinical Medicine, The University of New South Wales, Sydney, NSW, Australia.
Michael MichaelPeter MacCallum Cancer Centre, Parkville, VIC, Australia.
Sanja MirkovPharmacy Department, Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia.
Emma MorrisPharmacy Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Carol A PollockFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Darren M RobertsSchool of Clinical Medicine, The University of New South Wales, Sydney, NSW, Australia.
David J RoutledgeThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Carla ScuderiSchool of Pharmacy, University of Queensland, Brisbane, QLD, Australia.
Julia ShingletoneviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Jake ShorttMonash Haematology, Monash Health, Clayton, VIC, Australia.
Jim SiderovPharmacy Department, Austin Health, Melbourne, VIC, Australia.
Ben SprangersBiomedical Research Institute, Department of Immunology and Infection, UHasselt, Diepenbeek, Belgium.
Brian N SteinICON Cancer Centre, Adelaide, SA, Australia.
Amanda TeyPharmacy Department, Monash Health, Clayton, VIC, Australia.
Kate WebberDepartment of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Jenny WichartAlberta Health Services, Alberta, Canada.
Rachel WongDepartment of Medical Oncology, Eastern Health, Box Hill, VIC, Australia.
Robyn L WardFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
ADDIKD Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems. Funding: Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources.

Indexed as

ChemotherapyDrug dosingHaematologyKidney dysfunctionOncologyPharmacokineticsRenal

Identifiers

PMID40290844
PMCPMC12034076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.